MCM
APLS

Moore Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Moore Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150,000
Closed -$5.71M – 437
2023
Q3 		$5.71M Buy
150,000
+143,000
+2,043% +$6.28M 0.11% 141
2023
Q2 		$638K Buy
+7,000
New +$604K 0.01% 330

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Moore Capital Management's APLS Position: Q2 2023 in Review

Moore Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2023, closing a stake of 75,000 shares — an estimated $6.47M sold.

Moore Capital Management first reported a position in APLS in Q1 2019 and held it in 4 quarters. The position peaked at $12.3M in Q3 2022. 317 funds tracked by Wall St. Rank hold APLS as of Q2 2023.

  • Moore Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Moore Capital Management sold 75,000 Apellis Pharmaceuticals shares in Q2 2023, an estimated $6.47M.
  • Moore Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • Moore Capital Management's Apellis Pharmaceuticals position peaked at $12.3M in Q3 2022.
  • 317 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2023.

Based on Moore Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.